glp 1 glucagon dual receptor agonist Science Behind GIP and Agonists for Obesity Research | News & Announcements PDB-101: Molecule of the Month:

BiNan Lu, [email protected] Disclaimer All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers

4 Global estimates also reveal substantial regional variation in adolescent obesity prevalence, reflecting differences in socioeconomic status, urbanization, dietary patterns, and physical activity levels (Table 1)

Wilding J

10.1016/j.cmet.2013.04.008 [DOI] [PubMed] [Google Scholar] 6.Sun L, Zheng ZM, Shao CS, Zhang ZY, Li MW, Wang L, Wang H, Zhao GH, Wang P (2022) Rational design by structural biology of industrializable, long-acting antihyperglycemic GLP-1 receptor agonists

Both procedures can produce significant weight loss, but they work in different ways and may fit different patients